Tasos Zografidis, Ph.D. has been appointed vice president of Clinical Operations at Anavex Life Sciences Corp. In this newly created position, Dr. Zografidis will be responsible for managing Anavex's clinical programs, including the upcoming Phase IIa trial for ANAVEX 2-73 and ANAVEX PLUS, the company's lead drug candidate combination for Alzheimer's disease.
Dr. Zografidis has more than 25 years of experience in the pharma and healthcare industry, having spent 12 years at Wyeth in clinical project management and most recently served as a clinical and pharmaceutical consultant. At Wyeth, Dr. Zografidis spearheaded population pharmacokinetics analysis and its implementation in the clinical setting and positively differentiated compounds. Dr. Zografidis first joined Wyeth in 1998 as a product manager.
"Dr. Zografidis is a tremendous addition to our management team and I am very pleased to welcome him to Anavex," said Christopher U. Missling, Ph.D., president and chief executive officer of Anavex.